chr2-21011802-C-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_000384.3(APOB):c.5066G>A(p.Arg1689His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00171 in 1,614,062 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.0014 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0017 ( 2 hom. )
Consequence
APOB
NM_000384.3 missense
NM_000384.3 missense
Scores
2
4
10
Clinical Significance
Conservation
PhyloP100: 1.25
Genes affected
APOB (HGNC:603): (apolipoprotein B) This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins (LDL), and is the ligand for the LDL receptor. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Dec 2019]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.1047526).
BS2
High Homozygotes in GnomAdExome4 at 2 SD gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
APOB | NM_000384.3 | c.5066G>A | p.Arg1689His | missense_variant | 26/29 | ENST00000233242.5 | NP_000375.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
APOB | ENST00000233242.5 | c.5066G>A | p.Arg1689His | missense_variant | 26/29 | 1 | NM_000384.3 | ENSP00000233242.1 | ||
APOB | ENST00000673739.2 | n.*4372G>A | non_coding_transcript_exon_variant | 25/25 | ENSP00000501110.2 | |||||
APOB | ENST00000673739.2 | n.*4372G>A | 3_prime_UTR_variant | 25/25 | ENSP00000501110.2 |
Frequencies
GnomAD3 genomes AF: 0.00136 AC: 207AN: 152082Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
207
AN:
152082
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00128 AC: 322AN: 251174Hom.: 1 AF XY: 0.00128 AC XY: 174AN XY: 135730
GnomAD3 exomes
AF:
AC:
322
AN:
251174
Hom.:
AF XY:
AC XY:
174
AN XY:
135730
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00174 AC: 2546AN: 1461862Hom.: 2 Cov.: 34 AF XY: 0.00173 AC XY: 1255AN XY: 727232
GnomAD4 exome
AF:
AC:
2546
AN:
1461862
Hom.:
Cov.:
34
AF XY:
AC XY:
1255
AN XY:
727232
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00136 AC: 207AN: 152200Hom.: 0 Cov.: 33 AF XY: 0.00117 AC XY: 87AN XY: 74404
GnomAD4 genome
AF:
AC:
207
AN:
152200
Hom.:
Cov.:
33
AF XY:
AC XY:
87
AN XY:
74404
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
7
ALSPAC
AF:
AC:
3
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
25
ExAC
AF:
AC:
163
Asia WGS
AF:
AC:
3
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:7Benign:11
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:3Benign:3
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Jun 22, 2021 | This variant is associated with the following publications: (PMID: 20657596, 27153395, 26036859, 26415676, 19602640, 30681615, 26582918) - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 09, 2023 | The APOB c.5066G>A; p.Arg1689His variant (rs151009667), also known as Arg1662His for legacy nomenclature, is reported in the literature in individuals with familial hypercholesterolemia (Johansen 2010, Radovica-Spalvina 2015), but is also reported to not segregate with disease in one study (Braenne 2016). However, this variant is reported to be positively associated with familial hypercholesterolemia in a Saudi population with an odds ratio of 45.07 (95% CI: 2.67-759.1; p=0.0001) and may be a risk factor (Batais 2019). The p.Arg1689His variant is reported in ClinVar (Variation ID: 189304). It is observed in the general population with an overall allele frequency of 0.1% (387/282574 alleles) in the Genome Aggregation Database. Computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.222). Due to conflicting information, the significance of this variant is uncertain at this time. References: Batais MA et al. Screening of common genetic variants in the APOB gene related to familial hypercholesterolemia in a Saudi population: A case-control study. Medicine (Baltimore). 2019 Jan;98(4):e14247. PMID: 30681615. Braenne I et al. Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction. Eur J Hum Genet. 2016 Feb;24(2):191-7. PMID: 26036859. Johansen CT et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet. 2010 Aug;42(8):684-7. PMID: 20657596. Radovica-Spalvina I et al. Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population. BMC Med Genet. 2015 Sep 28;16:86. PMID: 26415676. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Dec 27, 2019 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Apr 10, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | May 12, 2023 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2024 | APOB: BP4 - |
Hypercholesterolemia, familial, 1 Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | research | Laboratory of Genetics and Molecular Cardiology, University of São Paulo | Mar 01, 2016 | - - |
Likely benign, criteria provided, single submitter | research | Institute for Integrative and Experimental Genomics, University of Luebeck | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Robarts Research Institute, Western University | - | - - |
Hypercholesterolemia, autosomal dominant, type B;C4551990:Familial hypobetalipoproteinemia 1 Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | New York Genome Center | Apr 20, 2021 | The c.5066G>A (p.Arg1689His) variant identified in the APOB gene substitutes a conserved Arginine for Histidine at amino acid 1689/4564 (exon 26/29). This variant is found in gnomAD(v3.1.1) (207 heterozygotes, 0 homozygotes; allele frequency: 1.36e-3), and there is one homozygote present in population data from gnomAD(v2.1.1) (387 heterozygotes, 1 homozygote; allele frequency: 1.37e-3). In silico algorithms predict this variant to be Damaging (SIFT; score:0.003) and Benign (REVEL; 0.222) to the function of the canonical transcript. This variant is reported as both a Variant of Uncertain Significance and Likely Benign in ClinVar (VarID:189304). This variant has been reported in several affected individuals in the literature [PMID: 20657596,26415676,26036859, 30681615], although it does not segregate with disease in some studies [PMID:26036859]. The p.Arg1689 residue is not within a mapped domain of APOB (UniProtKB:P04114). The c.5066G>A (p.Arg1689His) variant identified in the APOB gene is reported as a Variant of Uncertain Significance. - |
not specified Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Mar 12, 2019 | - - |
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Oct 02, 2017 | p.Arg1689His in exon 26 of APOB: This variant is not expected to have clinical significance because it was identified in 0.3% (342/126440) of European chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org/; dbSNP rs151009667). In addition, while it has been reported in 5 individuals with hypertriglyceridemia or a history of early myocardial infarction, it did not segregate with disease in 3 affected relatives from 3 families (Johansen 2010, Braenne 2015). This variant is reported in ClinVar (Variation ID:189304). ACMG/AMP Criteria applied: BS1, BS4 (Richards 2015). - |
Familial hypobetalipoproteinemia 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 03, 2018 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Hypercholesterolemia, autosomal dominant, type B Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Oct 03, 2018 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases allowed determination this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
APOB-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 04, 2022 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 27, 2018 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Familial hypercholesterolemia Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | May 02, 2018 | Likely Benign variant based on current evidence: This missense variant (also known as p.Arg1662His in the mature protein) is located in the beta 1 domain of the APOB protein. Computational prediction tools and conservation analyses suggest that this variant may not impact the protein function. Computational splicing tools suggest that this variant may not impact the RNA splicing. To our knowledge this variant has not been investigated for functional impact in experimental studies nor has the variant been reported in individuals affected with familial hypercholesterolemia in the literature. In a study of individuals affected with myocardial infarction, carrier status of this variant showed no correlation with cholesterol levels (PMID: 26036859). This variant has been identified in 342/126440 non-Finnish European chromosomes (0.27%) in the general population by the Genome Aggregation Database (gnomAD). This variant allele frequency is greater than expected for the disorder based on prevalence, penetrance, and genetic/allelic heterogeneity. Based on available evidence, this variant is classified as Likely Benign. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Pathogenic
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Benign
D
M_CAP
Benign
T
MetaRNN
Benign
T
MetaSVM
Benign
T
PrimateAI
Benign
T
PROVEAN
Uncertain
D
REVEL
Benign
Sift
Uncertain
D
Sift4G
Pathogenic
D
Vest4
MVP
MPC
ClinPred
T
GERP RS
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at